Concepedia

Author

Lee H. Pai-Scherf

National Cancer Institute

Also Known As

L H Pai-Scherf, Lee H. Pai-Scherf, Lee Pai-Scherf

16

Publications

840

Citations

9

H-Index

38

Concepts

All Affiliations

National Cancer InstituteUnited States Food and Drug AdministrationCenter for Drug Evaluation and Research
LH

About

Lee H. Pai-Scherf is an author at National Cancer Institute specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

367

2

Health Sciences

2

2

151

3

Allergy

1

1

52

4

Clinical Immunology

1

1

52

5

Hepatology

1

1

108

Lee H. Pai-Scherf

×

6

Publications

653

Citations

6

H-Index

YearCitations

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li,

The Oncologist

2017

286

Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.

Lee H. Pai-Scherf, J Villa, Deborah A. Pearson,

PubMed

1999

108

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions

Janice Kim, Diana Bradford, Erin Larkins,

Clinical Cancer Research

2021

99

FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.

Harpreet Singh, Geoffrey Kim, V. Ellen Maher,

Journal of Clinical Oncology

2016

71

Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1

Raffit Hassan, Juanita Williams-Gould, Thelma M. Watson,

Clinical Cancer Research

2004

52

Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.

Lee H. Pai-Scherf, Jorge A. Carrasquillo, Chang H. Paik,

PubMed

2000

37

Page 1